|
市場調査レポート
商品コード
1420114
セファロスポリン医薬品の世界市場:世代別、投与経路別、用途別、地域別、国別の分析、市場考察、予測Global Cephalosporin Drug Market : Analysis by Generation, Route of Administration, Application, By Region, By Country: Market Insights and Forecast |
||||||
|
セファロスポリン医薬品の世界市場:世代別、投与経路別、用途別、地域別、国別の分析、市場考察、予測 |
出版日: 2024年02月01日
発行: Azoth Analytics
ページ情報: 英文 260 Pages
納期: 即納可能
![]() |
世界のセファロスポリン医薬品の市場規模は、2022年の132億7,000万米ドルから2029年末までに219億米ドルに達すると予測されます。世界のセファロスポリン医薬品市場の有利な成長要因は、細菌感染症の流行、抗生物質耐性パターン、規制承認、新しい製剤の導入によって推進されています。2024年~2029年の予測期間に世界のセファロスポリン医薬品はCAGRで7.5%の拡大が見込まれます。製薬企業は、耐性菌に対抗するため、先進の世代のセファロスポリン製剤の開発に注力しています。新世代の開発、併用療法、徐放性製剤、適応症の拡大などが、いずれもセファロスポリン医薬品の進化に寄与しています。
呼吸器感染症、尿路感染症、皮膚・軟部組織感染症、腹腔内感染症などの細菌感染症の世界中での高い罹患率とその増加は、重要な促進要因です。セファロスポリンは、これらの感染症の治療に一般的に処方される抗生物質であり、セファロスポリン医薬品の需要が促進されています。
世界の医薬品サプライチェーンは、パンデミック中、ロックダウン、輸送制限、工場閉鎖による混乱に直面しました。これらの混乱は、セファロスポリン医薬品を含む医薬品の生産、流通、入手に影響を与えました。しかし、影響を緩和し、必要不可欠な医薬品の継続的な供給を確保する活動がなされました。また、パンデミックは進行中の臨床試験を中断させ、セファロスポリン医薬品の開発に関連する臨床試験を含む新たな臨床試験の開始を遅らせました。この中断は、新しいセファロスポリンの導入や、その利用の拡大に関するスケジュールに影響を与えた可能性があります。
進行中の研究開発では、吸入可能な製剤や新しい呼吸器デバイスなど、先進のドラッグデリバリーシステムの開発が行われています。これらの技術は、セファロスポリン医薬品の気道への標的送達を強化し、有効性を向上させ、副作用を最小限に抑えることを目的としています。
徐放性製剤は、セファロスポリン製剤を長時間にわたって徐々に放出するように設計されており、投与回数を減らすことができます。これにより、患者の服薬アドヒアランスと利便性が向上します。放出制御機構などのドラッグデリバリー技術の進歩により、治療効果の持続性が確保され、急速な薬剤放出に伴う副作用のリスクが軽減される可能性があります。
医薬品製造における連続製造プロセスは、効率性、費用対効果、品質管理の面で利点があります。これらのプロセスをセファロスポリンの製造に応用することで、より合理的でスケーラブルな製造パイプラインが実現します。また、スマートパッケージングでは、RFID(Radio-Frequency Identification)やQRコードのような技術を取り入れることで、医薬品の保管状況をモニターし、有効期限を追跡し、製品全体の完全性を高めることができます。これにより、ライフサイクルを通してセファロスポリン医薬品の品質と安定性が保証されます。
当レポートでは、世界のセファロスポリン医薬品市場について調査し、市場規模と予測、地域とセグメントの分析、主要動向と機会などの情報を提供しています。
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: Cephalosporin Drug in Pipeline
Table A3: United States Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A4: United States Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A5: United States Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A6: United States Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A7: United States Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A8: United States Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A9: Canada Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A10: Canada Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A11: Canada Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A12: Canada Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A13: Canada Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A14: Canada Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A15: Rest of Americas Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A16: Rest of Americas Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A17: Rest of Americas Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A18: Rest of Americas Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A19: Rest of Americas Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A20: Rest of Americas Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A21: United Kingdom Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A22: United Kingdom Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A23: United Kingdom Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A24: United Kingdom Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A25: United Kingdom Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A26: United Kingdom Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A27: Germany Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A28: Germany Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A29: Germany Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A30: Germany Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A31: Germany Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A32: Germany Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A33: France Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A34: France Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A35: France Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A36: France Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A37: France Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A38: France Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A39: Italy Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A40: Italy Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A41: Italy Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A42: Italy Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A43: Italy Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A44: Italy Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A45: Rest of Europe Cephalosporin Drug Market , By Generation, By Value, 2019-2022 (USD Million)
Table A46: Rest of Europe Cephalosporin Drug Market , By Generation, By Value, 2023-2029 (USD Million)
Table A47: Rest of Europe Cephalosporin Drug Market , By Route of Administration, By Value, 2019-2022 (USD Million)
Table A48: Rest of Europe Cephalosporin Drug Market , By Route of Administration, By Value, 2023-2029 (USD Million)
Table A49: Rest of Europe Cephalosporin Drug Market , By Application, By Value, 2019-2022 (USD Million)
Table A50: Rest of Europe Cephalosporin Drug Market , By Application, By Value, 2023-2029 (USD Million)
Table A51: China Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A52: China Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A53: China Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A54: China Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A55: China Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A56: China Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A57: Japan Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A58: Japan Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A59: Japan Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A60: Japan Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A61: Japan Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A62: Japan Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A63: South Korea Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A64: South Korea Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A65: South Korea Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A66: South Korea Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A67: South Korea Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A68: South Korea Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A69: India Cephalosporin Drug Market, By Generation, By Value, 2019-2022 (USD Million)
Table A70: India Cephalosporin Drug Market, By Generation, By Value, 2023-2029 (USD Million)
Table A71: India Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A72: India Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A73: India Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A74: India Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A75: Rest of Asia-Pacific Cephalosporin Drug Market, By Generation Industry, By Value, 2019-2022 (USD Million)
Table A76: Rest of Asia-Pacific Cephalosporin Drug Market, By Generation Industry, By Value, 2023-2029 (USD Million)
Table A77: Rest of Asia-Pacific Cephalosporin Drug Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A78: Rest of Asia-Pacific Cephalosporin Drug Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A79: Rest of Asia-Pacific Cephalosporin Drug Market, By Application, By Value, 2019-2022 (USD Million)
Table A80: Rest of Asia-Pacific Cephalosporin Drug Market, By Application, By Value, 2023-2029 (USD Million)
Table A81: Lupin Key Financials, 2020-2022
Table A82: Baxter International Key Financials, 2020-2022
Table A83: Roche Key Financials, 2020-2022
Table A84: Eli Lilly and Company Key Financials, 2020-2022
Table A85: Abbott Laboratories Key Financials, 2020-2022
Table A86: Merck & Co., Inc. Key Financials, 2020-2022
Table A87: Novartis Key Company Financials, 2020-2022
Table A88: Sanofi Key Financials, 2020-2022
Table A89: Pfizer Key Financials, 2020-2022
Table A90: Teva Pharmaceuticals Key Company Financials, 2020-2022
Azoth Analytics has released a research report titled "Global Cephalosporin Drug Market (2024 Edition)" which provides a complete analysis of the Global Cephalosporin Drug industry in terms of market segmentation By Generation (First Generation, Second Generation, Third Generation, Fourth Generation, Fifth Generation), By Route of Administration (Oral, Parenteral), By Application (Respiratory Tract Infection, Skin Infection, Urinary Tract Infection, Others), By Region (Americas , Europe, Asia-pacific, Middle-East & Africa), for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.
The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, France, Italy, China, Japan, South Korea, India). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.
The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.
The Global Cephalosporin Drug Market is expected to generate USD 21.9 Billion by the end of 2029, up from USD 13.27 Billion in 2022. A favourable growth element for the global Cephalosporin Drug market is propelled by the prevalence of bacterial infections, antibiotic resistance patterns, regulatory approvals, and the introduction of new formulations. During the forecast period, 2024-2029, Global Cephalosporin Drug is expected to expand at a CAGR of 7.5%. Pharmaceutical companies have focused on developing advanced generations of Cephalosporin drugs to combat bacterial resistance. The development of new generations, combination therapies, extended-release formulations, and expanded indications all contribute to the evolving landscape of Cephalosporin drugs.
The high and growing incidence of bacterial infections worldwide, such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections, is a significant driving factor. Cephalosporins are commonly prescribed antibiotics for treating these infections, which fuels the demand for Cephalosporin drugs.
The global pharmaceutical supply chains faced disruptions due to lockdowns, transportation restrictions, and factory closures during the pandemic. These disruptions affected the production, distribution, and availability of pharmaceutical products, including Cephalosporin drugs. However, efforts were made to mitigate the impact and ensure a continued supply of essential medications. Also, the pandemic disrupted ongoing clinical trials and delayed the initiation of new trials, including those related to the development of Cephalosporin drugs. This interruption may have impacted the timeline for introducing new Cephalosporins or exploring their expanded uses.
According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), Globally, the incidence of Upper Respiratory Infection reached 17*2 billion. Ongoing research involves the development of advanced drug delivery systems, such as inhalable formulations or novel respiratory devices. These technologies aim to enhance the targeted delivery of cephalosporin drugs to the respiratory tract, improving efficacy and minimizing side effects.
Extended-release formulations are designed to release the cephalosporin drug gradually over an extended period, allowing for less frequent dosing. This can lead to improved patient adherence and convenience. Advances in drug delivery technologies, such as controlled-release mechanisms, ensure a sustained therapeutic effect and potentially reduce the risk of side effects associated with rapid drug release.
Continuous manufacturing processes in pharmaceutical production offer advantages in terms of efficiency, cost-effectiveness, and quality control. Applying these processes to cephalosporin production contribute to a more streamlined and scalable manufacturing pipeline. Also, Smart packaging involves incorporating technologies like RFID (Radio-Frequency Identification) or QR codes to monitor drug storage conditions, track expiration dates, and enhance overall product integrity. This ensures the quality and stability of cephalosporin drugs throughout their lifecycle.